Latest "Zenobia Therapeutics" News Stories - Page: 4

10:12 EST 12th December 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 76–100 of 8,100+

Probably Relevant

e-Therapeutics (ETX) - Releasing hidden value

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics (ETX) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson’s disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information from C4XD’s platform. This has...

Akebia Therapeutics to merge with Keryx Biopharmaceuticals

US-based biopharmaceutical firm Akebia Therapeutics has signed a definitive agreement to merge with Keryx Biopharmaceuticals to form a fully integrated...Read More... The post Akebia Therapeutics to merge with Keryx Biopharmaceuticals appeared first on Pharmaceutical Technology.

Cerebral Therapeutics gets $3M boost

A round of Series A financing has been closed by Aurora, Colo.-based Cerebral Therapeutics at $3 million.  -More- 

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

Patent granted for groundbreaking work by Jennifer Doudna’s and Emmanuelle Charpentier’s research teams in CRISPR/Cas9 genome editing technologyPatent covers use of optimized guide RNA molecules ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences,...

STAT Plus: SQZ Therapeutics pushes forward with its method to squeeze drugs into cells

SQZ Therapeutics is working on a new way to get medicines into cells — and it's had a very busy fall.

Avenue Therapeutics, Inc. (ATXI) InvaGen Announces Acquisition Agreement with Avenue Therapeutics Conference Call (Transcript)

Deals this week: Biohaven Therapeutics, POXEL, Ossianix

Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease....Read More... The post Deals this week: Biohaven Therapeutics, POXEL, Ossianix appeared first on Drug Development Technology.

Why Pluristem Therapeutics believe that in cell therapy “the process is the product”

Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics

Will Axsome Therapeutics Make Big Strides?

Shares of Axsome Therapeutics Inc. (AXSM) have returned 15% so far this month while the iShares Nasdaq Biotechnology ETF (IBB) has gained just 3% for the same period.

Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences

CRISPR Therapeutics will develop novel immune-oncology therapies after entering an agreement to use MaxCyte’s cell engineering platform. The partnership is an...Read More... The post Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences appeared first on Drug Development Technology.

Neon Therapeutics files for IPO

Neon Therapeutics Inc. (immuno-oncology) filed for its initial public offering.

United Therapeutics to Co-Develop MannKind's Dry Powder Treprostinil for PAH

United Therapeutics has agreed to license and co-develop MannKind’s clinical-phase dry powder formulation of the pulmonary arterial hypertension (PAH) treatment treprostinil—the active ingredient in United Therapeutics’ top-selling drugs Remodulin® and Tyvaso®—through a collaboration that could generate more than $95 million for MannKind, the companies said today. Under their...

Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum

Drug makers are making more bets on the nascent field of digital medicine. The latest example: Click Therapeutics announced Monday that it grabbed a $17 million investment led by Sanofi Ventures, the Cambridge, MA-based venture capital arm of the French pharmaceutical giant. New York-based Click Therapeutics develops mobile apps intended to be prescribed by doctors […]

MannKind and United Therapeutics to advance dry powder treprostinil

US-based biopharmaceutical company MannKind has entered an exclusive licensing and collaboration agreement with United Therapeutics over a dry powder formulation...Read More... The post MannKind and United Therapeutics to advance dry powder treprostinil appeared first on Pharmaceutical Technology.

vTv Therapeutics shares soar on licensing tie-up with Chinese group Newsoara Biopharma

Newsoara will develop vTv Therapeutics' HPP737 as a new treatment for chronic obstructive pulmonary disease

Have You Checked Checkpoint Therapeutics Yet?

Shares of Checkpoint Therapeutics Inc. (CKPT), a majority controlled subsidiary of Fortress Biotech Inc. (FBIO), are well off their highs recorded last September, and trade around $3.

Arena Pharmaceuticals Snags $800 Million from United Therapeutics for a Phase III PAH Drug

United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag.

LNC Therapeutics gets IP from Cornell

LNC Therapeutics licensed exclusive rights to Christensenella patents from Cornell University.

BriaCell Therapeutics announces positive proof of concept data in treating breast cancer

Briacell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) CEO William Williams speaks with Proactive Investor's Christine Corrado at the MicroCap Conference in New York. BriaCell Therapeutics Corp. is an immuno-oncology company which develops immunotherapy treatments for cancer. BriaCell is currently focused on the clinical development of Bria-IMT™ as a 2nd line treatment for patients with adva...

e-Therapeutics (ETX) - Keeping the faith

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics’ (ETX) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug Discovery (NDD) platform, out-licensing its NDD-derived preclinical immunoncology (I/O) assets and financial prudence. The H118 operating loss was £2.8m. Cash outflow was &po...

Nestle Health increases stake in Aimmune Therapeutics

Nestlé Health Science has raised its equity stake in biopharmaceutical firm Aimmune Therapeutics to around 19% with an investment of...Read More... The post Nestle Health increases stake in Aimmune Therapeutics appeared first on Pharmaceutical Technology.

Realm Therapeutics Provides Update on Strategic Review

MALVERN, Pa., Nov. 29, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized Read more...

Health Canada approves United Therapeutics' neuroblastoma drug

United Therapeutics' PrUnituxin, or dinutuximab, in combination with granulocyte-macrophage colony-stimulating factor, interl -More- 

TG Therapeutics and Novimmune Forge $185M Agreement

TG Therapeutics and Novimmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies.

Modus Therapeutics raises $15.7M to fund sickle cell candidate trials

A Series A funding round brought in about $15.7 million for Swedish biotech Modus Therapeutics, which the company will use to -More- 

Quick Search


News Quicklinks